Gastric carcinoma gene znf312b, a protein translated from the gene, and a diagnostic kit and a screening method for anticancer agents using the same

A screening method for stomach cancer inducers comprising the following steps:

• a) treating stomach originated cells with a sample composition or sample compound as an experimental group;
• b) measuring and comparing expression levels of ZNF312b marker gene comprising SEQ ID NO:1 or a fragment thereof between the experimental group of step a) and a non-treated control group;
• and
• c) selecting the sample composition or the sample compound significantly increasing the expression level of the 3NF312b marker gene or a fragment thereof in the experimental group, compared with the non-treated control group.

A screening method for stomach cancer inhibitors comprising the following steps:

• a) treating stomach originated cells with a sample composition or sample compound as an experimental group;
• b) measuring and comparing expression levels of ZNF312b marker gene comprising SEQ ID NO:1 or a fragment thereof between the experimental group of step a) and a non-treated control group;
• and
• c) selecting the sample composition or the sample compound significantly decreasing the expression level of the ZNF312b marker gene or a fragment thereof in the experimental group, compared with the non-treated control group.

A screening method for stomach cancer inducers comprising the following steps:

• a) preparing a gene construct containing a reporter gene operably linked to ZNF312b promoter comprising a nucleotide sequence comprising SEQ ID NO:9 or a fragment thereof;
• b) preparing a transformant by transfecting animal cell lines with an expression vector inserted with the gene construct of step a);
• c) preparing an experimental group by treating the transformant of step b) with a sample composition or sample compound;
• d) measuring expression levels of the reporter gene in the experimental group and a control group of transformants not treated with the sample composition or sample compound;
• and
• e) selecting the sample composition or the sample compound significantly increasing the expression level of the gene in the experimental group of step d), compared with the control group.

A screening method for stomach cancer inhibitors comprising the following steps:

• a) preparing a gene construct containing a reporter gene operably linked to ZNF312b promoter composed of nucleotide sequence comprising SEQ ID NO:9 or a fragment thereof;
• b) preparing a transformant by transfecting animal cell lines with an expression vector inserted with the gene construct of step a);
• c) preparing an experimental group by treating the transformant of step b) with a sample composition or sample compound;
• d) measuring expression levels of the reporter gene in the experimental group and a control group of transformants not treated with the sample composition or sample compound;
• and
• e) selecting the sample composition or the sample compound significantly decreasing the expression level of the gene in the experimental group of step d), compared with the control group.

A screening method for stomach cancer inducers comprising the following steps:

• a) preparing a gene construct containing a reporter gene operably linked to a K-ras promoter comprising a nucleotide sequence comprising SEQ ID NO:
• 15 or a fragment thereof;
• b) preparing a transformant by transfecting animal cell lines expressing ZNF312b protein comprising an amino acid sequence comprising SEQ ID NO:2 or a fragment thereof with an expression vector inserted with the gene construct of step a);
• c) preparing an experimental group by treating the transformant of step a) with a sample composition or sample compound;
• d) measuring expression levels of the reporter gene in the experimental group and a control group of transformants not treated with a sample composition or sample compound;
• and
• e) selecting the sample composition or the sample compound significantly increasing the expression level of the gene in the experimental group of step d), compared with the control group.

A screening method for stomach cancer inhibitors comprising the following steps:

• a) preparing a gene construct containing a reporter gene operably linked to a K-ras promoter comprising a nucleotide sequence comprising SEQ ID NO:15 or a fragment thereof;
• b) preparing a transformant by transfecting animal cell lines expressing ZNF312b protein comprising an amino acid sequence SEQ ID NO:
• 2 or a fragment thereof with an expression vector inserted with the gene construct of step a);
• c) preparing an experimental group by treating the transformant of step b) with a sample composition or sample compound;
• d) measuring expression levels of the reporter gene in the experimental group and a control group of transformants not treated with a sample composition or sample compound;
• and
• e) selecting the sample composition or the sample compound significantly decreasing the expression level of the gene in the experimental group of step d), compared with the control group.

A screening method for stomach cancer inducers comprising the following steps:

• a) treating oligonucleotide containing a K-ras promoter comprising a nucleotide sequence comprising SEQ ID NO:15 or a fragment thereof with ZNF312b protein comprising an amino acid sequence comprising SEQ ID NO:2 or a fragment thereof together with a sample composition or a sample compound;
• b) measuring and comparing a binding level of ZNF312b protein or the fragment thereof with the K-ras promoter or the fragment thereof between the treated group of step a) and a non-treated control group;
• and
• c) selecting the sample composition or the sample compound significantly increasing the binding level in the experimental group, compared with the non-treated control group.

A screening method for stomach cancer inhibitors comprising the following steps:

• a) treating oligonucleotide containing a K-ras promoter comprising a nucleotide sequence comprising SEQ ID NO:15 or a fragment thereof with ZNF312b protein comprising an amino acid sequence comprising SEQ ID NO:2 or a fragment thereof together with a sample composition or a sample compound;
• b) measuring and comparing a binding level of ZNF312b protein or the fragment thereof with the K-ras promoter or the fragment thereof between the treated group of step a) and a non-treated control group;
• and
• c) selecting the sample composition or the sample compound significantly decreasing the binding level in the experimental group, compared with the control group.